|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CSF3R |
Gene summary for CSF3R |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CSF3R | Gene ID | 1441 |
| Gene name | colony stimulating factor 3 receptor | |
| Gene Alias | CD114 | |
| Cytomap | 1p34.3 | |
| Gene Type | protein-coding | GO ID | GO:0002376 | UniProtAcc | Q99062 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 1441 | CSF3R | RNA-P10T2-P10T2-3 | Human | Lung | AAH | 2.06e-02 | 7.10e-01 | -0.1408 |
| 1441 | CSF3R | RNA-P6T2-P6T2-1 | Human | Lung | IAC | 4.11e-25 | 7.39e-01 | -0.0166 |
| 1441 | CSF3R | RNA-P6T2-P6T2-2 | Human | Lung | IAC | 1.05e-29 | 8.21e-01 | -0.0132 |
| 1441 | CSF3R | RNA-P6T2-P6T2-3 | Human | Lung | IAC | 2.45e-34 | 8.29e-01 | -0.013 |
| 1441 | CSF3R | RNA-P6T2-P6T2-4 | Human | Lung | IAC | 7.27e-23 | 6.91e-01 | -0.0121 |
| 1441 | CSF3R | RNA-P7T1-P7T1-1 | Human | Lung | AIS | 5.96e-04 | 6.71e-01 | -0.0961 |
| 1441 | CSF3R | RNA-P7T1-P7T1-2 | Human | Lung | AIS | 1.19e-04 | 6.40e-01 | -0.0876 |
| 1441 | CSF3R | RNA-P7T1-P7T1-3 | Human | Lung | AIS | 1.11e-04 | 6.88e-01 | -0.0822 |
| 1441 | CSF3R | RNA-P7T1-P7T1-4 | Human | Lung | AIS | 2.24e-03 | 5.28e-01 | -0.0809 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00300998 | Lung | IAC | myeloid cell differentiation | 70/2061 | 381/18723 | 1.12e-05 | 3.45e-04 | 70 |
| GO:00456378 | Lung | IAC | regulation of myeloid cell differentiation | 36/2061 | 210/18723 | 4.70e-03 | 3.68e-02 | 36 |
| GO:19037068 | Lung | IAC | regulation of hemopoiesis | 56/2061 | 367/18723 | 7.23e-03 | 4.94e-02 | 56 |
| GO:003009913 | Lung | AIS | myeloid cell differentiation | 63/1849 | 381/18723 | 3.05e-05 | 9.70e-04 | 63 |
| GO:004563713 | Lung | AIS | regulation of myeloid cell differentiation | 35/1849 | 210/18723 | 1.43e-03 | 1.74e-02 | 35 |
| GO:003009923 | Lung | AAH | myeloid cell differentiation | 29/613 | 381/18723 | 2.44e-05 | 3.42e-03 | 29 |
| GO:004563721 | Lung | AAH | regulation of myeloid cell differentiation | 16/613 | 210/18723 | 1.55e-03 | 3.86e-02 | 16 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa041514 | Lung | IAC | PI3K-Akt signaling pathway | 60/1053 | 354/8465 | 7.03e-03 | 2.86e-02 | 1.90e-02 | 60 |
| hsa0415111 | Lung | IAC | PI3K-Akt signaling pathway | 60/1053 | 354/8465 | 7.03e-03 | 2.86e-02 | 1.90e-02 | 60 |
| hsa0415121 | Lung | AIS | PI3K-Akt signaling pathway | 57/961 | 354/8465 | 3.72e-03 | 2.00e-02 | 1.28e-02 | 57 |
| hsa0415131 | Lung | AIS | PI3K-Akt signaling pathway | 57/961 | 354/8465 | 3.72e-03 | 2.00e-02 | 1.28e-02 | 57 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| CSF3 | CSF3R | CSF3_CSF3R | CSF3 | Breast | Healthy |
| CSF3 | CSF3R | CSF3_CSF3R | CSF3 | Cervix | ADJ |
| CSF3 | CSF3R | CSF3_CSF3R | CSF3 | Cervix | CC |
| CSF3 | CSF3R | CSF3_CSF3R | CSF3 | Cervix | Healthy |
| CSF3 | CSF3R | CSF3_CSF3R | CSF3 | Endometrium | EEC |
| CSF3 | CSF3R | CSF3_CSF3R | CSF3 | Esophagus | ESCC |
| CSF3 | CSF3R | CSF3_CSF3R | CSF3 | HNSCC | ADJ |
| CSF3 | CSF3R | CSF3_CSF3R | CSF3 | HNSCC | OSCC |
| CSF3 | CSF3R | CSF3_CSF3R | CSF3 | HNSCC | Precancer |
| CSF3 | CSF3R | CSF3_CSF3R | CSF3 | Prostate | BPH |
| CSF3 | CSF3R | CSF3_CSF3R | CSF3 | Prostate | Healthy |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CSF3R | SNV | Missense_Mutation | novel | c.1868N>A | p.Gly623Glu | p.G623E | Q99062 | protein_coding | tolerated(1) | benign(0) | TCGA-AC-A8OQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CSF3R | SNV | Missense_Mutation | c.353N>C | p.Arg118Pro | p.R118P | Q99062 | protein_coding | deleterious(0.02) | possibly_damaging(0.589) | TCGA-AO-A124-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| CSF3R | SNV | Missense_Mutation | novel | c.1783C>G | p.Leu595Val | p.L595V | Q99062 | protein_coding | deleterious(0.04) | benign(0.039) | TCGA-BH-A0DX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
| CSF3R | SNV | Missense_Mutation | c.2220N>G | p.Asn740Lys | p.N740K | Q99062 | protein_coding | tolerated(0.19) | benign(0.006) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | |
| CSF3R | SNV | Missense_Mutation | c.540G>T | p.Lys180Asn | p.K180N | Q99062 | protein_coding | tolerated(0.11) | benign(0) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CSF3R | SNV | Missense_Mutation | c.2476N>T | p.Thr826Ser | p.T826S | Q99062 | protein_coding | tolerated(0.67) | benign(0.019) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CSF3R | insertion | Nonsense_Mutation | novel | c.1957_1958insTATGTCGTCCGGAAACCAGGTAGGAGTTCCTA | p.Asn653IlefsTer8 | p.N653Ifs*8 | Q99062 | protein_coding | TCGA-B6-A0IE-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | ||
| CSF3R | deletion | Frame_Shift_Del | novel | c.630delG | p.Thr211ProfsTer15 | p.T211Pfs*15 | Q99062 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| CSF3R | SNV | Missense_Mutation | novel | c.1222C>A | p.Leu408Ile | p.L408I | Q99062 | protein_coding | tolerated(0.06) | possibly_damaging(0.799) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| CSF3R | SNV | Missense_Mutation | novel | c.1801N>T | p.Met601Leu | p.M601L | Q99062 | protein_coding | deleterious(0.01) | benign(0.291) | TCGA-C5-A905-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 1441 | CSF3R | CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | Filgrastim-SNDZ | FILGRASTIM | ||
| 1441 | CSF3R | CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | FILGRAMSTIM | |||
| 1441 | CSF3R | CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | PLX7486 | |||
| 1441 | CSF3R | CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | agonist | CHEMBL1201568 | PEGFILGRASTIM | |
| 1441 | CSF3R | CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | MAXY-G34 | |||
| 1441 | CSF3R | CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | INS-19 | |||
| 1441 | CSF3R | CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | agonist | 178101632 | FILGRASTIM | |
| 1441 | CSF3R | CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | PLX-5622 | PLX-5622 | 22294205 | |
| 1441 | CSF3R | CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | GLYCOPEG-GCSF | |||
| 1441 | CSF3R | CLINICALLY ACTIONABLE, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | FILGRASTIM | FILGRASTIM |
| Page: 1 2 3 4 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |